NCT04888039 Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
| NCT ID | NCT04888039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-12-15 |
| Primary Completion | 2031-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2021-12-15 with a primary completion date of 2031-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions. Treatments choice for medical care of patient with MM depends of their age, their general status, their eligibility to high dose treatment (autograft), and also based on cytogenetic risk (standard/high risk). Therapeutic strategies are multiple and based on drugs associations including proteasome inhibitors, immuno-modulators and monoclonal antibodies. Therapeutic medical care objective is to improve quality and response duration through more effective induction schemas, systematic consolidation for patients who have undergone high dose therapy and/or maintenance treatment, ensuring patients safety and well-being in the health care pathway. Quality of life evaluation has to take in consideration disease outcome and secondary effects impact from treatments prescribed for MM. With clinical trials, new therapeutic strategies are proposed with innovative drugs but participants are selected and do not represent all patients with MM. Therefore, there is a large gap between clinical trials and real life data. That's why the CHU Toulouse intends to set up a prospective cohort to evaluate the health care pathway of patients with MM in West-Occitanie region and studies impact of treatments prescribed on the disease and on the patients' quality of life. With this research, standard of care practices for patients with MM will be followed, prognostic scores and clinical trials results will be validated in real life, impact of outpatient support procedure will be assessed (AMA procedure) and sociodemographic/quality of life data will be available for research teams.
Eligibility Criteria
Inclusion Criteria: * Patient living in the West-Occitanie region * Patient with a diagnosis of symptomatic multiple myeloma (Rajkumar et al, Lancet Oncology 2014) Exclusion Criteria: * Patient opposed to this research * Patient under legal protection
Contact & Investigator
Aurore PERROT, MD
PRINCIPAL INVESTIGATOR
IUCT-Oncopole - Toulouse University Hospital
Frequently Asked Questions
Who can join the NCT04888039 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04888039 currently recruiting?
Yes, NCT04888039 is actively recruiting participants. Contact the research team at perrot.aurore@iuct-oncopole.fr for enrollment information.
Where is the NCT04888039 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT04888039 clinical trial?
NCT04888039 is sponsored by University Hospital, Toulouse. The principal investigator is Aurore PERROT, MD at IUCT-Oncopole - Toulouse University Hospital. The trial plans to enroll 2,000 participants.